William J. Garner, MD

Founder & Director

Dr. Garner is a physician, investor, inventor and entrepreneur who has founded and co-founded numerous life science companies, including Race Oncology, Tryp Therapeutics, and Isla Pharmaceuticals, among others. In addition to serving as Founder and Managing Director of EGB Ventures, Dr. Garner has served in management roles and on the boards of a number of EGB Ventures portfolio companies. Prior to EGB, Dr. Garner held positions in the medical affairs division of Hoffmann LaRoche – Oncology and at a merchant banking firm in New York City.

Dr. Garner earned a Master of Public Health from the Harvard T.H. Chan School of Public Health and an MD at New York Medical College. Dr. Garner trained in the Anatomic Pathology residency program at Columbia-Presbyterian, was a pre-doctoral fellow at the Mass General Cancer Center, and is currently a licensed physician in the State of New York.

Roland Boivin

Chief Executive Officer

Mr. Boivin brings nearly 25 years of public company leadership experience, with a focus on strategic operations, finance, business development, and general management. Before joining GeneTether as CEO in 2021, he served as CFO at Medexus Pharmaceuticals, Inc. (formerly Pediapharm Inc.), a TSX-listed company focused on innovative rare disease treatment solutions. Among his many accomplishments in that role, Mr. Boivin led the company’s 2013 reverse takeover transaction, helped manage its graduation from the TSXV to the TSX, and played an integral role in its transformative acquisition of two speciality pharma companies. Previously, he held a variety of progressive positions at 3M Canada, including leading the company’s Consumer Division as Business Unit Manager, and was member of its Executive Committee. Mr. Boivin holds a Bachelor of Commerce in Marketing and Entrepreneurship from McGill University and an Executive MBA from Queen’s University.

John Rothman, PhD

Chief Scientific Officer

Dr. Rothman brings over 30 years of experience in product development across various therapeutic areas and markets. In addition to serving as the Chief Scientific Officer of EGB portfolio company Race Oncology (ASX: RAC), he has previously served as a clinical scientist and in senior executive positions at numerous pharmaceutical and biopharmaceutical companies, including Schering-Plough and Roche, where he was the Senior Director of Clinical Drug Development with responsibilities for all data collection, analysis, and reporting for Roche’s portfolio. He oversaw the first clinical trial in AIDS and has managed the development of numerous marketed drugs, including Interferon, Rocephin, and Versed.

Dr. Rothman studied for his Ph.D. in Pharmacology at Tulane University School of Medicine in the laboratory of Dr. Louis Ignarro (Nobel Prize in Medicine – 1998). He conducted his dissertation research at the New Orleans VA Hospital in the laboratory of Dr. Andrew Schally and was a graduate student there when Dr. Schally won the Nobel Prize in Medicine in 1977.

Jim O’Neill

Chief Financial Officer

Mr. O’Neill has over 30 years of experience as a finance executive with publicly listed and private multi-national businesses operating in Canada, the U.S., the UK, Turkey, and Kenya. Most recently, Mr. O’Neill was Chief Financial Officer of Tryptamine Therapeutics (ASX: TYP), successfully leading the company through its migration to Australia and listing on the Australian Securities Exchange. Mr. O’Neill founded and currently serves as president of O’Neill & O’Neill Services Corp. providing financial consulting services including CFO and corporate secretarial services to TSXV and CSE listed companies, as well as private businesses. Mr. O’Neill also previously served as chief financial officer for various public and private companies with responsibilities including cash flow management, fundraising, financing, investment analysis, and evaluating potential merger and acquisition opportunities. He received his bachelor’s in business administration from Wilfrid Laurier University and holds a CPA and CA from the Chartered Professional Accountants of Canada.

André Fraga

Director

André Pereira Fraga Figueiredo is the founding partner of Aurea Holdings and has over 20 years of experience in M&A, Strategy and Business Development, first in the Petrochemical sector and later in the Renewable Energy sectors, operating in Europe, South America and Asia. In addition, he is an active investor in life science companies, participating in early-stages fund raising, as well as venture formation. Prior to founding Aurea Holdings, he was General Manager of Renovatio Group and Renovatio Eco-Solutions. He serves as a director of OnOn Holdings. Mr. Fraga obtained his undergraduate in Business Studies from Universidade Católica Portuguesa, holds an International MBA from Instituto de Empresa (IE) and has undertaken an Executive Education Program at Harvard Business School.

P. Gage Jull

Director

Mr. Jull is a co-founder and Chairman of Bordeaux Capital Inc., a Toronto-based mergers & acquisitions advisory firm focused on emerging companies in the natural resources and other sectors. Mr. Jull also holds the position of Executive Chairman for Arrow Exploration. He also acted as a Director and Chairman of the Special Committee for Aldridge Minerals Inc. Prior to Bordeaux Capital, Mr. Jull was a Managing Director, Corporate Finance at Mackie Research Capital Corp., an investment banking, and securities brokerage firm. Mr. Jull has experience working on numerous cross border equity and debt offerings involving energy assets around the world, with capital sourced in Canada, the U.S. and the U.K. At Prudential Bache Mr. Jull was the lead banker on the $40 million cross border Initial Public Offering of Quadra Logic Technologies a Vancouver based pharmaceutical company. He has completed over 200 financings and M&A transactions in the course of his career. Mr. Jull holds a BSc degree from the University of Toronto, an MBA from the University of Western Ontario, and PEng and CFA designations.

Daren Graham

Executive Chairman

Mr. Graham has over 20 years of experience in the life science industry as a merchant banker, senior operations executive, and corporate finance attorney. Prior to transitioning to full time Executive Chairman of Rize, he was Chief Operating Officer of EGB Ventures, Chairman of GeneTether Therapeutics, and special advisor to Tryp Therapeutics. Previously he was a Co-Founder of Osteon Therapeutics, Managing Director of Allele Capital Partners, Executive Director in Tribal Capital Markets’ Equity Capital Life Sciences Division, and Chief Legal Officer and Vice President of Strategic Development at Sancilio Pharmaceuticals Company. Mr. Graham began his career as a corporate finance attorney in the Boston headquarters of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo PC, representing both private and public life science companies in private and public financings.

After receiving a BBA in Finance from Northeastern State University of Oklahoma, Mr. Graham earned his Juris Doctorate from Boston College Law School. He is a member of the Massachusetts Bar (active) and holds FINRA Series 7, 63 and 79 licenses (inactive). He is a citizen of the Cherokee Nation.